Professeur Ralph GRÄSBECK (1996) Université d'Helsinki (FINLANDE) Professeur James STEICHEN (1997) Université d'Indianapolis, Canada) Professeur Marc LEVENSTON (2005) Institute of Technology, 1996. ,
Evolving epidemiology of hepatitis C virus, Clinical Microbiology and Infection, vol.17, issue.2, pp.107-122, 2011. ,
DOI : 10.1111/j.1469-0691.2010.03432.x
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges, Gastroenterology, vol.146, issue.5 ,
DOI : 10.1053/j.gastro.2014.03.003
The pleiotropic actions of vitamin D, BioEssays, vol.62, issue.1, pp.21-29, 2004. ,
DOI : 10.1128/MCB.15.10.5789
Vitamin D and the Immune System: New Perspectives on an Old Theme, Endocrinology and Metabolism Clinics of North America, vol.39, issue.2, pp.365-79, 2010. ,
DOI : 10.1016/j.ecl.2010.02.010
2624-?? 8. 10 Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C, Digestive Diseases and Sciences, pp.43-50, 2010. ,
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C, Hepatology, vol.376, issue.Suppl. 2, pp.1118-1144, 2011. ,
DOI : 10.1016/S0140-6736(10)60588-0
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C1641-?? 50 Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI Combined effect of 25- OH vitamin D plasma levels and genetic Vitamin DReceptor (NR 1I1) variants on fibrosis progression rate in HCV patients, al. 1(OH) Vitamin D3 Supplementation Improves the Sensitivity of the Immune-Response during Peg-IFN/RBV Therapy in Chronic Hepatitis C Patients-Case Controlled Trial. Makishima M, éditeur. PLoS ONE. 23 mai, pp.756-61635, 2010. ,
Impact of Vitamin D Supplementation on Sustained Virological Response in Chronic Hepatitis C Genotype 4 Patients Treated by Pegylated Interferon/Ribavirin, Journal of Interferon & Cytokine Research, vol.35, issue.1, 2014. ,
DOI : 10.1089/jir.2014.0060
Telaprevir for retreatment of HCV infection Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatmentnaive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Boceprevir for untreated chronic HCV genotype 1 infection, N Engl J Med. 23 juin Lancet. 28 août N Engl J Med. 31 mars, vol.23364364376364, issue.3513, pp.2405-2421, 2009. ,
Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection, World Journal of Gastroenterology, vol.11, issue.12, pp.1843-1850, 2005. ,
DOI : 10.1056/NEJM196902062800605
Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus Early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C Ribavirin, but not interferon alpha-2b, is associated with impaired osteoblast proliferation and differentiation in vitro Lack of evidence for ribavirininduced bone loss, Journal of Medical Virology. mars Dig Dis Sci. juill J Hepatol. nov Calcif Tissue Int. août Hepatology. juill, vol.8245337536, issue.37521, pp.390-395, 2000. ,
Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon ? and ribavirin therapy Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients, Journal of Viral Hepatitis. juill Gastroenterology. mars, vol.44128, issue.3, pp.636-677, 2005. ,
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance, Nature, vol.18, issue.7262, pp.399-401, 2009. ,
DOI : 10.1038/nature08309